This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Shire (SHP.L) – Will no longer pursue the development of Vyvanse following a clinical trial of the medicine for the treatment of major depressive disorder. Closing Price 3141p (Sharecast)
Royal Dutch Shell (RDSa.L & RDSb.L) – Russia’s Bashneft said on Friday its board had approved a deal to buy oil from Shell worth up to $1.4bn before February 2016. Closing Price 2104.00p & 2223.50p respectively (Reuters)
Aquarius Platinum (AQP.L) – Revenue decreased by 2% to $113m. Group cash balance at period end of $83m. Continue to produce at capacity but impacted by a low pgm dollar price. Despite the primary deficit in PGM metal markets during the 2013 calendar year which is forecast to increase in 2014. Results H1 were negatively impacted by strikes at Anglo Platinum in October and the Christmas break in operations. Closing Price 39.00p. (Reuters)
AstraZeneca (AZN.L) – Is advancing experimental drugs into late- stage clinical trials faster than expected in a bid to replace sales that it’s losing to generic competitors. Three medicines that may move into final-stage development this year have potential for peak annual sales of at least $1bn. Closing Price 3815.50p (Reuters)
Vodafone (VOD.L) – $1.6bn plan to buy out the local partners in its Indian unit won government approval. Closing Price 223.90p (Bloomberg)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Supergroup | SGP.L | 7.24% | 8.58% | -0.67% |
| EasyJet | EZJ.L | 2.53% | 2.71% | 0.18% |
| Vodafone | VOD.L | 2.21% | 2.83% | -0.59% |
| TUI Travel | TT.L | -0.14% | 0.97% | -2.57% |
| Smith & Nephew | SN.L | 2.46% | 2.74% | 0.97% |
| Faroe Petroleum | FPM.L | 1.13% | 2.08% | -0.23% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research